Our Services
Medical Information
Helpful Resources
Published on: 3/12/2026
There are several factors to consider: IBD is an autoimmune misfire that can keep inflaming the gut despite treatment, and 30 to 40 percent of people do not reach durable remission on first-line therapies due to loss of response, side effects, or aggressive disease; see below to understand more.
Clinical trials can provide access to advanced options and close monitoring but carry real risks, including no benefit or placebo, disease worsening, unknown side effects, medication restrictions, and a heavy visit burden; see the complete guidance below on trial phase, rescue plans, cost coverage, alternatives, and warning signs that may require urgent care and a doctor discussion.
If you're living with inflammatory bowel disease (IBD) — including Crohn's disease or ulcerative colitis — you may feel like your gut keeps failing you. Even with modern medications, many people continue to struggle with flares, pain, diarrhea, fatigue, and uncertainty.
When standard treatments don't work, doctors may suggest participating in a clinical trial. While research trials are critical for advancing treatment, it's important to understand the risks of joining an IBD clinical trial before deciding.
Let's break this down clearly and honestly — without fear, but without false reassurance either.
IBD is not just a "sensitive stomach." It is a chronic autoimmune condition in which the immune system mistakenly attacks the digestive tract. Over time, this can lead to:
Even with treatment, about 30–40% of patients do not achieve long-term remission with first-line therapies such as mesalamine, corticosteroids, immunomodulators, or biologics.
There are several reasons why treatment may fail:
When this happens, doctors may discuss experimental therapies being tested in clinical trials.
Clinical trials are carefully controlled research studies that test:
These trials follow strict ethical and safety regulations overseen by institutional review boards (IRBs) and government agencies.
Clinical trials are essential. Many of today's effective IBD medications — including anti-TNF agents and newer biologics — were once trial drugs.
But participating is not without risk.
When considering the risks of joining an IBD clinical trial, it's important to look at both medical and practical factors.
This is the most straightforward risk.
In moderate to severe IBD, untreated inflammation can cause complications. Clinical trials often allow "rescue medications," but there may be restrictions.
By definition, clinical trials test treatments that are not fully understood.
Potential risks include:
Earlier-phase trials (Phase I or II) carry more uncertainty than large Phase III trials.
While safety monitoring is rigorous, rare side effects sometimes only become clear after larger populations are treated.
Clinical trials often require:
This can be physically and emotionally draining, especially if you are already fatigued.
Some trials require stopping:
This can temporarily destabilize your disease.
Even if the medication works, long-term risks may not yet be fully known. Some immune-modulating drugs have historically been linked (rarely) to:
While these events are uncommon, they are important to understand.
Hope can be powerful — and so can disappointment.
Clinical trials can create:
It's important to weigh psychological readiness as well as physical health.
It's equally important not to ignore the potential benefits.
Many participants experience:
Some breakthrough IBD treatments have dramatically improved quality of life for patients who had exhausted all options.
You may consider discussing this option if:
But it should never be rushed.
Before enrolling, ask your doctor:
If you're still suffering, don't assume it's "normal." Persistent symptoms could indicate:
Common warning signs include:
If you're experiencing these warning signs and want to better understand whether they may be related to Ulcerative Colitis, a free AI-powered symptom checker can help you assess your symptoms and prepare informed questions before your next doctor's appointment.
However, an online tool is not a diagnosis. It is simply a starting point.
IBD is complex. It involves:
No single therapy works for everyone because the underlying immune pathways differ between patients.
This is why clinical research continues — and why personalized medicine is becoming more important in IBD care.
When thinking about the risks of joining an IBD clinical trial, balance three things:
How uncontrolled is your inflammation? What are the risks of doing nothing?
Have you truly exhausted approved options?
Are you comfortable with uncertainty?
A good clinical team will never pressure you.
IBD can feel relentless. When symptoms persist, it's easy to feel like your gut is failing you. In reality, your immune system is misfiring — and medicine is still learning how to control it safely and effectively.
Clinical trials are not reckless experiments. They are structured, regulated, and often offer hope. But they are not guarantees.
The risks of joining an IBD clinical trial include:
The potential benefits include:
There is no universally "right" decision. There is only the right decision for you.
If you are experiencing:
Seek urgent medical care.
For any ongoing symptoms, worsening flares, or questions about clinical trials, speak directly to a qualified healthcare professional. IBD can become life-threatening if complications are ignored.
You deserve clear information, thoughtful guidance, and a plan that prioritizes both safety and quality of life.
Your gut may feel like it's failing — but with the right support, evaluation, and medical partnership, you still have options.
(References)
* Regueiro M, Cross RK, D'Haens G, Ferrante M, Gralnek IM, Kaser A, Kim SC, Lévêque M, Ma C, Peyrin-Biroulet L, Rubin DT, Sands BE, Schinzari G, Singh S. Unmet Needs in Inflammatory Bowel Disease. Gastroenterology. 2023 Dec;165(7):1661-1674. doi: 10.1053/j.gastro.2023.09.006. Epub 2023 Sep 13. PMID: 37709325.
* Glassner KL, Abraham BP, Quigley EMM. The gut microbiome in inflammatory bowel disease: Current understanding and future challenges. Gut. 2020 Feb;69(2):373-382. doi: 10.1136/gutjnl-2019-318536. Epub 2019 Sep 26. PMID: 31558564; PMCID: PMC6998858.
* Lu H, Li H, Song T, Xu Y, Li M, Ma G, Chen G. Safety of biologics and small molecules for inflammatory bowel disease: a systematic review and meta-analysis of randomized controlled trials. Lancet Gastroenterol Hepatol. 2023 Apr;8(4):321-337. doi: 10.1016/S2468-1253(22)00392-1. Epub 2023 Feb 1. PMID: 36738555.
* Ungaro RC, D'Haens G, Peyrin-Biroulet L, Vermeire S, Sands BE. Challenges and Future Directions in Inflammatory Bowel Disease Clinical Trials. Gastroenterology. 2022 Jun;162(7):1914-1930. doi: 10.1053/j.gastro.2022.02.046. Epub 2022 Mar 1. PMID: 35246210; PMCID: PMC9133878.
* Feagan BG, Sands BE, Loftus EV Jr, D'Haens G, Peyrin-Biroulet L, Bortlik M, Panés J, Schreiber S, Danese S, Vermeire S, Rogler G, Jairath V, Hanauer SB, Regueiro M, Sartor RB, Colombel JF, Travis SPL, Van Assche G, Bernstein CN, Dotan I, O'Byrne S, Reinisch W, Stronati L, Targan SR, Uzzan B, Watson AR. Inflammatory bowel disease: an overview of the current and future therapeutic landscape. Lancet Gastroenterol Hepatol. 2022 Dec;7(12):1160-1172. doi: 10.1016/S2468-1253(22)00216-1. Epub 2022 Oct 11. PMID: 36240974.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.